The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma.
 
Antoni Ribas
Stock and Other Ownership Interests - Compugen; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; GlaxoSmithKline; Merck; Novartis
Research Funding - Merck Sharp & Dohme (Inst)
 
Marcus Butler
Honoraria - Bayer; Merck; Roche Pharma AG
Consulting or Advisory Role - Merck; Novartis; Roche Pharma AG
Research Funding - MedImmune (Inst)
 
Jose Lutzky
Honoraria - Bristol-Myers Squibb; Genentech/Roche
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche
Research Funding - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Merck; Merck Serono; Millennium; Novartis; Onconova Therapeutics; Prometheus; Viralytics
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Prometheus
 
Donald P. Lawrence
Research Funding - MedImmune (Inst)
 
Caroline Robert
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche Pharma AG
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche Pharma AG
Research Funding - MedImmune (Inst)
 
Wilson Miller
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche Pharma AG
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche Pharma AG
Research Funding - MedImmune (Inst)
Travel, Accommodations, Expenses - Novartis; Roche Pharma AG
 
Gerald P. Linette
Research Funding - MedImmune (Inst)
 
Paolo Antonio Ascierto
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche/Genentech; Ventana Medical Systems
Research Funding - Bristol-Myers Squibb; MedImmune (Inst); Roche/Genentech; Ventana Medical Systems
 
Timothy Kuzel
Honoraria - Amgen; Argos Therapeutics; Astellas Pharma; Bayer/Onyx; Bionomics; Celgene; Eisai; Genentech/Roche; Janssen
Speakers' Bureau - Astellas Pharma; Bayer; Celgene; Genentech/Roche; Janssen Oncology
Research Funding - Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); CureTech (Inst); Eisai (Inst); Genentech/Roche (Inst); MedImmune (Inst); Merck/Schering Plough (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Argos Therapeutics; Astellas Pharma; Bayer/Onyx; Celgene; elorac; Genentech; Janssen Oncology
 
Alain Patrick Algazi
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; OncoSec; Plexxikon
 
Michael Andrew Postow
Consulting or Advisory Role - Amgen; Bioconnections LLC; FirstWord; Millennium
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Paul D. Nathan
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - MedImmune (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Brendan D. Curti
Honoraria - Prometheus
Research Funding - Bristol-Myers Squibb (Inst); MedImmune (Inst); Prometheus (Inst)
Travel, Accommodations, Expenses - Agonox; Prometheus
 
Paul B. Robbins
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca
 
Xia Li
Employment - MedImmune
 
John A. Blake-Haskins
Employment - MedImmune; MedImmune (I)
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca (I); GlaxoSmithKline; GlaxoSmithKline (I)
 
Michael S. Gordon
Research Funding - GlaxoSmithKline; MedImmune